SCOTUS signals willingness to tackle skinny label questions worrying generic drug industry

SCOTUS signals willingness to tackle skinny label questions worrying generic drug industry

The Supreme Court's request for Solicitor General input increases the chances of a hearing on skinny-label controversies

Unlock unlimited access to all IAM content